Enoxaparin solution for injections 10000 anti-Cha IU/ml. 3 ml. vial №1


Manufacturer: Switzerland

Prevention of venous thromboembolism in surgical interventions that are accompanied by a moderate or high thrombogenic risk; prevention of blood clots in the extracorporeal circulation circuit during hemodialysis, which lasts 4 hours or less; deep vein thrombosis, without severe clinical signs, with the exception of pulmonary embolism requiring treatment with thrombolytic drugs or surgical intervention; in combination with acetylsalicylic acid for the treatment of unstable angina and acute myocardial infarction without a q wave; in combination with a thrombolytic drug for the treatment of acute myocardial infarction with elevation or elevation of the ST segment, in patients who may undergo angioplasty in the future, as well as if they do not.



Enoxaparin Composition
Active substance: enoxaparin;

1 ml of 10,000 anti-Ha IU, which is equivalent to 100 mg of enoxaparin sodium;

Excipients: benzyl alcohol, water for injection.

Sodium is contraindicated for use in patients with the following conditions:

hypersensitivity to sodium, heparin or its derivatives, including other low molecular weight heparins;
a history of immune-mediated heparin-induced thrombocytopenia (HIT) within the last 100 days in the presence of circulating antibodies;
active clinically significant bleeding and conditions with a high risk of bleeding, including recent hemorrhagic stroke, gastrointestinal ulcer, the presence of a malignant neoplasm with a high risk of bleeding, recent surgery on the brain, spinal cord, or eyes, known or suspected varicose veins of the esophagus, arteriovenous malformations, vascular aneurysms, or serious malformations of intraspinal or intracerebral vessels;
spinal or epidural anesthesia or locoregional anesthesia if enoxaparin sodium has been used for treatment within the previous 24 hours.

Mode of application
The route of administration is subcutaneous (except for patients with myocardial infarction with ST segment elevation, who need an intravenous bolus).

Recommended for adults.

The drug should not be administered intramuscularly.

1 ml of solution for injection is equivalent to approximately 10,000 anti-Xa IU of enoxaparin.

Application features
It sodium should be prescribed to pregnant women only if the doctor establishes a clear need for such treatment.


1 mg protamine neutralizes the anticoagulant effect of 100 IU (1 mg) of sodium if sodium was administered within the previous 8 hours.
Protamine infusion at a dose of 0.5 mg for every 100 IU (1 mg) of enoxaparin sodium can be used if enoxaparin sodium has been administered more than 8 hours prior to protamine use or if a second dose of protamine has been determined.
12 hours after the administration of enoxaparin sodium, the use of protamine may not be necessary.
However, even with the use of high doses of protamine, the anti-Xa activity of enoxaparin sodium is never fully neutralized (maximum about 60%) (see Instructions for use of protamine salts).